BackgroundCheck.run
Search For

Carl L Sparrow, 40121 Towne Creek Dr, Villa Rica, GA 30180

Known as:
Carl Sparow
Related to:
Donald La Jones 64 Diane Brown Jones 65

Carl Sparrow Phones & Addresses

121 Towne Creek Dr, Villa Rica, GA 30180    404-2857805   

Trenton, NJ   

Dayton, NJ   

Edison, NJ   

Douglasville, GA   

Larue, TX   

Monmouth Junction, NJ   

Kennesaw, GA   

Get Report
Control this profile

Mentions for Carl L Sparrow

Carl Sparrow resumes & CV records

Resumes

Carl Sparrow Photo 20

Producer And Songwriter And Engineer

Location:
121 Towne Creek Dr, Villa Rica, GA 30180
Industry:
Financial Services
Work:
Educational Testing Service (Ets) Jun 2016 - Jul 2018
Test Security Specialist Thornbird Msp Records Jan 1997 - May 2016
Producer and Songwriter and Engineer Metlife Jul 2010 - Oct 2015
Bd Imagining Specialist Pc Warehouse Aug 2007 - Dec 2008
Computer Repair Technician
Education:
West Central Tech 2003 - 2004
Lithia Springs High School 1999 - 2003
Skills:
Leadership, Management, Microsoft Office, Microsoft Excel, Microsoft Word, Powerpoint, Process Improvement, Research, Computer Hardware, Training, Project Management, Financial Analysis, Customer Service, Team Building, Communication, Business Process Improvement, Social Media, Strategic Planning, Audio Compliance
Carl Sparrow Photo 21

Carl Sparrow

Carl Sparrow Photo 22

Carl Sparrow

Location:
United States
Carl Sparrow Photo 23

Carl Sparrow

Publications & IP owners

Us Patents

Method For The Prevention And/Or Treatment Of Atherosclerosis

US Patent:
2003008, May 8, 2003
Filed:
Oct 1, 2002
Appl. No.:
10/261710
Inventors:
Carl Sparrow - Westfield NJ, US
John Ondeyka - Fanwood NJ, US
Bruno Tse - Jersey City NJ, US
Sheo Singh - Edison NJ, US
International Classification:
A61K039/395
A61K038/17
US Classification:
424/143100, 514/012000
Abstract:
The instant invention provides a method for raising serum HDL cholesterol levels comprising administering a therapeutically effective amount of an LXR ligand to a patient in need of such treatment. It further provides a method for using an LXR ligand to stimulate expression of the ABCgene. LXR ligands can be used for preventing and treating atherosclerosis and related conditions.

Antagonists Of Pcsk9

US Patent:
2010004, Feb 18, 2010
Filed:
Nov 2, 2007
Appl. No.:
12/312383
Inventors:
Ayesha Sitlani - Metuchen NJ, US
Carl P. Sparrow - Westfield NJ, US
Shilpa Pandit - Edison NJ, US
Jon H. Condra - Doylestown PA, US
Dana D. Wood - Collegeville PA, US
Timothy S. Fisher - Plainsboro NJ, US
International Classification:
A61K 39/395
C07K 16/18
C07H 21/00
C12N 15/74
C12N 5/07
C12P 21/02
G01N 33/53
A61P 35/00
US Classification:
4241331, 5303873, 536 2353, 4353201, 435325, 435 696, 435 721
Abstract:
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Antagonists Of Pcsk9

US Patent:
2010004, Feb 18, 2010
Filed:
Nov 2, 2007
Appl. No.:
12/312398
Inventors:
Carl P. Sparrow - Westfield NJ, US
Ayesha Sitlani - Metuchen NJ, US
Shilpa Pandit - Edison NJ, US
Jon H. Condra - Doylestown PA, US
Holly A. Hammond - Telford PA, US
International Classification:
A61K 39/395
C12P 21/02
C07H 21/02
C12N 15/74
C12N 5/071
A61P 35/00
US Classification:
4241331, 5303873, 536 2353, 4353201, 435325, 435 696
Abstract:
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Antagonists Of Pcsk9

US Patent:
2010004, Feb 18, 2010
Filed:
Nov 2, 2007
Appl. No.:
12/312401
Inventors:
Ayesha Sitlani - Metuchen NJ, US
Carl P. Sparrow - Westfield NJ, US
Shilpa Pandit - Edison NJ, US
Jon H. Condra - Doylestown PA, US
Holly A. Hammond - Telford PA, US
International Classification:
C12P 21/02
C07K 16/18
C07H 21/00
C12N 15/74
C12N 5/071
US Classification:
435 696, 5303873, 536 2353, 4353201, 435325
Abstract:
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Antagonists Of Pcsk9

US Patent:
2010013, Jun 3, 2010
Filed:
Nov 2, 2007
Appl. No.:
12/312397
Inventors:
Carl P. Sparrow - Westfield NJ, US
Ayesha Sitlani - Metuchen NJ, US
Shilpa Pandit - Edison NJ, US
Jon H. Condra - Doylestown PA, US
Holly A. Hammond - Telford PA, US
International Classification:
A61K 39/395
C07K 16/00
C07H 21/04
A61P 13/12
C12N 15/63
C12N 5/071
C12P 21/00
US Classification:
4241721, 5303891, 536 2353, 4353201, 435366, 435 696
Abstract:
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Antagonists Of Pcsk9

US Patent:
2010015, Jun 17, 2010
Filed:
Nov 2, 2007
Appl. No.:
12/312399
Inventors:
Carl P. Sparrow - Westfield NJ, US
Ayesha Sitlani - Metuchen NJ, US
Shilpa Pandit - Edison NJ, US
Jon H. Condra - Doylestown PA, US
Holly A. Hammond - Telford PA, US
International Classification:
A61K 39/395
C07K 16/00
C07H 21/04
A61P 9/00
A61P 3/00
C12N 15/63
C12N 5/00
C12P 21/06
US Classification:
4241581, 5303891, 536 2353, 4353201, 435325, 435 696
Abstract:
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Antagonists Of Pcsk9

US Patent:
2012007, Mar 29, 2012
Filed:
Sep 23, 2011
Appl. No.:
13/242809
Inventors:
Carl P. Sparrow - Westfield NJ, US
Ayesha Sitlani - Metuchen NJ, US
Shilpa Pandit - Edison NJ, US
Jon H. Condra - Doylestown PA, US
Holly A. Hammond - Telford PA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 39/395
C12N 15/13
A61P 7/00
A61P 9/00
C12N 1/19
C12N 15/63
C12P 21/02
C12N 5/10
C12N 1/21
C07K 16/40
A61P 3/00
US Classification:
4241581, 5303898, 536 2353, 4353201, 435 696, 435338, 43525233, 43525231, 43525235, 4352542
Abstract:
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Antagonists Of Pcsk9

US Patent:
2012007, Mar 29, 2012
Filed:
Sep 27, 2011
Appl. No.:
13/246219
Inventors:
Carl P. Sparrow - Westfield NJ, US
Ayesha Sitlani - Metuchen NJ, US
Shilpa Pandit - Edison NJ, US
Jon H. Condra - Doylestown PA, US
Holly A. Hammond - Telford PA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07K 16/40
C12N 15/63
C12N 1/19
C12P 21/02
C12N 1/21
C12N 15/13
C12N 5/10
US Classification:
5303898, 536 2353, 4353201, 435338, 435 692, 435419, 43525233, 43525231, 43525235, 4352542
Abstract:
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Possible Relatives

Cynthia D Sparrow  David G Sparrow  Dale Sparrow  Deborah Sparrow  Danae R Sparrow  Aaron D Sparrow  Denise R Sparrow  Carl Last  Carl D Johnson  Carl M Stamps 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.